We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Aromatase Inhibitors in the Treatment of Male Infertility

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00440180
Recruitment Status : Terminated (Not able meet target enrollment.)
First Posted : February 26, 2007
Results First Posted : March 7, 2016
Last Update Posted : April 6, 2016
Information provided by (Responsible Party):
University of Utah

February 22, 2007
February 26, 2007
February 5, 2016
March 7, 2016
April 6, 2016
March 2007
June 2014   (Final data collection date for primary outcome measure)
Pregnancy Rate [ Time Frame: 4 months ]
Partner pregnancy rate during study participation
Sperm concentration
Complete list of historical versions of study NCT00440180 on ClinicalTrials.gov Archive Site
Not Provided
Other sperm parameters, hormonal measures and pregnancy rates
Not Provided
Not Provided
Aromatase Inhibitors in the Treatment of Male Infertility
The Role of Aromatase Inhibitors in the Treatment of Infertility in Obese Male
Obesity is associated with an increase in blood levels of estrogen. Estrogen or "female hormone" is believed to have a negative effect on sperm production. Aromatase inhibitors such as anastrozole work to decrease the production of estrogen and increase testosterone in the body. By decreasing the level of estrogen, sperm production should improve. In this study, the investigators will try to determine the benefit of anastrozole in obese men and follow pregnancy outcomes.
Not Provided
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Obesity
  • Oligospermia
  • Drug: Anastrozole
    1 mg qd for 4 months
    Other Name: Arimidex
  • Drug: Placebo
    Placebo Comparator
  • Placebo Comparator: Group B
    Intervention: Drug: Placebo
  • Experimental: Group A
    Intervention: Drug: Anastrozole
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
June 2014
June 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Male partner of a couple presenting for infertility work up after one year of unprotected intercourse
  2. Moderate oligozoospermia (defined as mean sperm count ≤ 20 × 106/mL and ≥ than 3 × 106/mL) of at least two separate occasions spanning a minimum of two weeks
  3. Obese men BMI ≥ 30
  4. FSH and LH levels < 10 mIU/mL

Exclusion Criteria:

  1. Severe Oligozoospermia: Sperm count < than 3 × 106/mL, including azoospermia
  2. Age less than 18 or greater than 65 years
  3. Pyospermia or leukospermia: defined by white blood cells ≥ 1 million leukocytes per milliliter of semen
  4. Cryptorchidism
  5. Vasectomy reversal
  6. Regular use of tobacco products
  7. BMI < 30
  8. Use of anabolic steroids or testosterone replacement
  9. All patients with abnormal initial liver function tests "AST or ALT" will be excluded form the study
Sexes Eligible for Study: Male
16 Years to 80 Years   (Child, Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
University of Utah
University of Utah
Not Provided
Principal Investigator: Ahmad O Hammoud, MD University of Utah
University of Utah
March 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP